Literature DB >> 8609905

Distinct receptor domains determine subtype-specific coupling and desensitization phenotypes for human beta1- and beta2-adrenergic receptors.

G Rousseau1, F Nantel, M Bouvier.   

Abstract

Human beta1- and beta2-adrenergic receptor (beta1 AR and beta2 AR) coupling and desensitization characteristics were compared in defined heterologous expression systems. Significant differences in the coupling efficacies of the two subtypes were found in both Chinese hamster fibroblasts and murine Ltk- fibroblasts, which were used as surrogate cell lines. At the maximal level of stimulation with the nonselective beta-adrenergic agonist isoproterenol, beta1 AR-mediated adenylyl cyclase activation represented 70% and 20% of that mediated by beta2 AR in Chinese hamster and murine Ltk- fibroblasts, respectively. Sustained (15 min) stimulation with subsaturating concentration of isoproterenol (< 10% of receptor occupancy) led to identical desensitization of the beta-adrenergic-stimulated adenylyl cyclase activity for both beta1 AR and beta2AR-expressing cells. In contrast, when a nearly saturating concentration of isoproterenol (> 90% of receptor occupancy) was used to promote desensitization, the extent of desensitization observed for beta2 AR-expressing cells was 1.7-2-fold higher than that of the beta1 AR. The carboxyl domain of several G protein-coupled receptors has been shown to play important roles in both coupling efficacy and agonist-promoted desensitization. Therefore, we examined the contribution of this receptor domain in the subtype-selective phenotypes described above. A chimeric receptor composed of the first six transmembrane domains of the beta1 AR and of the seventh transmembrane domain and carboxyl tail of the beta2 AR maintained a coupling efficacy characteristic of the beta1 AR, whereas the extent of desensitization resulting from high receptor occupancy was identical to that of the beta2 AR. These results therefore suggest that the carboxyl portion of the beta1 AR and beta2 AR determines their subtype-selective desensitization patterns but not their respective coupling efficacies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609905

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor.

Authors:  Y Tang; L A Hu; W E Miller; N Ringstad; R A Hall; J A Pitcher; P DeCamilli; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Human beta1-adrenergic receptor is subject to constitutive and regulated N-terminal cleavage.

Authors:  Anna E Hakalahti; Miia M Vierimaa; Minna K Lilja; Esa-Pekka Kumpula; Jussi T Tuusa; Ulla E Petäjä-Repo
Journal:  J Biol Chem       Date:  2010-06-29       Impact factor: 5.157

Review 4.  The functional significance of genetic variation within the beta-adrenoceptor.

Authors:  A J Sandilands; K M O'Shaughnessy
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

5.  Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of beta-Adrenergic Receptors to Phosphoinositide 3-Kinase.

Authors:  Julie Simard; Matthieu Boucher; Rachel Massé; Terence E Hébert; Guy Rousseau
Journal:  Int J Cell Biol       Date:  2009-02-05

6.  A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA.

Authors:  Anjaparavanda P Naren; Bryan Cobb; Chunying Li; Koushik Roy; David Nelson; Ghanshyam D Heda; Jie Liao; Kevin L Kirk; Eric J Sorscher; John Hanrahan; John P Clancy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-26       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.